A new drug combo may shield kidney transplant patients from a common viral threat

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation. * Patient seropositive for CMV (confirmed within two weeks post-transplant) and having received an allograft from a CMV seropositive or seronegative donor. * Receiving a kidney transplant from a deceased or living donor with compatible ABO blood type. * Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study and two months later the discontinuation of the test drug. * Total ischemia time below 36 hours. * Capable of understanding the purpose and risks of the study. * Fully informed and having given written informed consent (signed Informed Consent has been obtained). * Affiliation to the social security regimen Exclusion Criteria: * CMV seronegative patient. * Historical or current TGI (French equivalence of calculated PRA) \> 85 % * Presence of historical or current anti-HLA donor specific antibodies * Patient who received anti-CMV therapy within the past 30 days prior to screening. * Receiving or having previously received an organ transplant other than a kidney. * Receiving a graft from a non-heart-beating donor. * Patient known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV; HBs Ag positive) or Hepatitis C (HCV; anti-HCV Ab positive).elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels ≥ 2 times the upper value of the normal range of the investigational site or receiving a graft from a hepatitis C or B positive donor. * Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer. * Known allergy or intolerance to everolimus, valganciclovir, ganciclovir, mycophenolic acid, basiliximab, corticosteroids, or cyclosporine A or any of the product excipients. * Severe hyperlipidemia defined by: total cholestérol ≥ 9,1 mmol/L (≥ 350 mg/dL) et/ou triglycérides ≥ 8,5 mmol/l (≥ 750 mg/dL) in spite an adequate medication. * Patient has adequate hematological post-transplant defined as: 1. Absolute neutrophil count (ANC) \> 1000 cells/μL. 2. Platelet count \> 50,000 cells/μL. 3. Hemoglobin \> 8.0 g/dL. * Requiring initial therapy with induction immunosuppressive antibody preparations, such as anti-thymocyte globulins or rituximab or IVIG. * Currently participating in another clinical trial investigating drugs. Observational studies are not considered as an exclusion criteria * Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator. * Unlikely to comply with the visits scheduled in the protocol.